EyePoint Pharmaceuticals, Inc. Forecast, price target & analysts
EyePoint Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation
EyePoint Pharmaceuticals, Inc. Classifications & Recommendation
EyePoint Pharmaceuticals, Inc. Price Target
| Target Price | $34.17 |
| Price | $3.85 |
| Potential |
787.53%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target EyePoint Pharmaceuticals, Inc. 2027 .
The average EyePoint Pharmaceuticals, Inc. target price is $34.17.
This is
787.53%
register free of charge
$71.40
1,754.55%
register free of charge
$5.05
31.17%
register free of charge
|
|
| A rating was issued by 19 analysts: 13 Analysts recommend EyePoint Pharmaceuticals, Inc. to buy, 6 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the EyePoint Pharmaceuticals, Inc. stock has an average upside potential 2027 of
787.53%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 31.37 | 1.77 |
| 27.50% | 94.37% | |
| EBITDA Margin | -768.66% | -20,711.06% |
| 130.48% | 2,594.42% | |
| Net Margin | -739.43% | -18,281.88% |
| 144.48% | 2,372.42% |
15 Analysts have issued a sales forecast EyePoint Pharmaceuticals, Inc. 2026 . The average EyePoint Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an EyePoint Pharmaceuticals, Inc. EBITDA forecast 2026. The average EyePoint Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 EyePoint Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2026. The average EyePoint Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.17 | -3.80 |
| 36.64% | 19.87% | |
| P/E | negative | |
| EV/Sales | 85.81 |
15 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast for earnings per share. The average EyePoint Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
EyePoint Pharmaceuticals, Inc....
Current EyePoint Pharmaceuticals, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| TD Cowen |
Locked
➜
Locked
|
Locked | Sep 02 2026 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 17 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
TD Cowen:
Locked
➜
Locked
|
Sep 02 2026 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Aug 17 2026 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 17 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
